A randomized controlled study on the application of optoelectronic technology and type A botulinum toxin in early intervention of linear scars after thyroid papillary carcinoma resection

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300075601

Enrollment

Unknown

Registered

2023-09-10

Start date

2023-09-01

Completion date

Unknown

Last updated

2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

scar

Interventions

Group A:Only use self-adhesive soft silicone dressings for continuous external application

Group B:laser therapy

Group C:Injection therapy of botulinum toxin type A

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) 18 years = age = 65 years; (2) Patients with papillary thyroid cancer within 1 week after resection; (3) Patients who voluntarily cooperate in completing all trials and follow-up; (4) We hope to prevent or improve patients with linear neck scars through drugs, optoelectronic technology, and type A botulinum toxin. (5) Agree to take photos and archive them before, after, and during follow-up visits; (6) Voluntarily participate in this clinical study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those who have a tendency to swallow, have difficulty breathing, or suffer from peripheral motor neuropathy; (2) Using corticosteroids, anticoagulants, and any medication or food that can cause photosensitivity reactions, as well as those exposed to sunlight and those who use isotretinoin; (3) There is an unhealed wound in the surgical area of the neck; Local skin infection and ulceration; (4) Suffering from blood system diseases such as active infections, immune suppression, and coagulation disorders; (5) Patients with peripheral vascular diseases and metabolic diseases; (6) During pregnancy or lactation; (7) Neuromuscular dysfunction; (8) Neurological disorders or mental disorders; (9) Allergies to silicone drugs; (10) The researchers believe that they are unable to cooperate in completing the follow-up study; (11) Unable to communicate normally.

Design outcomes

Primary

Measure	Time frame
Patient Observer Assessment Scale (POSAS);	—

Secondary

Measure	Time frame
VSS;Scar volume measurement;Observation of scar color and vascular proliferation by skin colorimeter and dermatoscope;Enzyme linked immunosorbent assay for detecting serum factors ;	—

Countries

China

Contacts

Public ContactRongxin Ren

Beijing Hospital

m13811497743_@163.com+86 132 4133 4914

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026